AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01868828
Drug: PAD
RxNorm normalized name: PAD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction Therapy of PAD for 4 cycles.
Trial: NCT01868828
Drug: VCD
RxNorm normalized name: STATLOCK PICC,VCDC ANCHOR DEVICE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction Therapy of VCD for 4 cycles.
Trial: NCT00551096
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine administered orally at 1660 mg/m2/day divided into two doses for 21 days followed by a week-off.
Trial: NCT00551096
Drug: ZD6474
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally at 300 mg/day once daily. One cycle will consist of 28 days
Trial: NCT03376932
Drug: FF/UMEC/VI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FF/UMEC/VI will be given as dry white powder delivered via the ELLIPTA DPI once daily in the morning or evening. The ELLIPTA DPI holds 2 individual blister strips with 30 blisters on each strip: the first strip contains FF 100 mcg or 200 mcg in each blister and the second strip contains UMEC 62.5 mcg and VI 25 mcg in each blister.
Trial: NCT03376932
Drug: FP/SAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FP/SAL will be given as dry white powder delivered via the DISKUS DPI twice daily in the morning or evening. The DISKUS DPI holds a single blister strip with 60 blisters, which contains FP 250 mcg or 500 mcg and SAL 50 mcg per blister.
Trial: NCT00800800
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 40 mg, oral, single dose
Trial: NCT00800800
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral, single dose
Trial: NCT02572375
Drug: Codeine Phosphate/Guaifenesin ER Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Provide two Codeine Phosphate and Guaifenesin ER Tablet every 12 hours for 6 1/2 days.
Trial: NCT02572375
Drug: Codeine Phosphate/Guaifenesin IR Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Provide one Codeine Phosphate and Guaifenesin IR Tablet every 4 hours for 6 1/2 days
Trial: NCT01345448
Drug: Placebo Lotion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Lotion dosed once.
Trial: NCT00005852
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00392093
Drug: Conjugated equine estrogens 0.625 mg/d + MPA 5 mg/d/10d
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01642550
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01971684
Drug: Second Line ITP agents
RxNorm normalized name: Gallus gallus gizzard lining preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The treating physicians will select the second line agent and clinical data will be collected.
Trial: NCT01923766
Drug: Cytotoxic T lymphocytes (CTLs).
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This Phase I dose-escalation trial is designed to evaluate the safety of donor-derived cytotoxic T lymphocytes (CTLs). Dose escalation is guided by the modified continual reassessment method (mCRM) in order to determine the maximum tolerated dose (MTD). For each group, MTD is defined as the dose at which the probability of DLT is at most 21%. Four dose levels are being evaluated namely, 5x106 cells/m2, 1.0x107 cells/m2, 1.5x107 cells/m2 and 2.5x107 cells/m2 with prior probabilities of toxicity estimated at 5%, 7.1%, 10% and 21%, respectively.~Two patients are allocated in each cohort and are followed for 30 days post IV injection for evaluation of DLTs. The trial continues until a minimum of 12 patients have been treated and stop when the maximum 18 patients have been treated.
Trial: NCT01162551
Drug: Sirolimus and Methotrexate
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Single Arm Efficacy Trial:~Sirolimus: Oral bolus on day 1, then daily oral dose days 2-28. Dose will be altered to maintain a sirolimus trough level between ≥ 8 and ≤ 13. Trough levels will be checked weekly.~Methotrexate: Oral 20 mg/m2/week on Days 2, 9, 16, 23.~One cycle is 28 days.
Trial: NCT01336244
Drug: GLPG0778
FDA approved: no
EMA approved: no
PMDA approved: no
Description: capsules containing 50 or 100 mg of GLPG0778
Trial: NCT01336244
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: multiple dose, aqueous formulation, 13 days days, matching ascending dose schedule
Trial: NCT00039013
Drug: AC2993
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Lead In (0.02 mL) for 4 weeks / AC2993 5mcg (0.02 mL) for 4 weeks / AC2993 5mcg (0.02 mL) for 26 weeks - All are subcutaneously injected twice daily
Trial: NCT00039013
Drug: AC2993
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Lead In (0.02 mL) for 4 weeks / AC2993 5 mcg (0.02 mL) for 4 weeks / AC2993 10 mcg (0.04 mL) for 26 weeks - All are subcutaneously injected twice daily
Trial: NCT00039013
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Lead In (0.02 mL) for 4 weeks / Placebo (0.02 mL) for 4 weeks / Placebo (0.02 mL) for 26 weeks - All are subcutaneously injected twice daily
Trial: NCT00039013
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Lead In (0.02 mL) for 4 weeks / Placebo mcg (0.02 mL) for 4 weeks / Placebo (0.04 mL) for 26 weeks - All are subcutaneously injected twice daily
Trial: NCT00308334
Drug: Placebo- Sugar pill
RxNorm normalized name: placebo Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo po TID x 14 days
Trial: NCT00532844
Drug: Sapropterin Dihydrochloride
RxNorm normalized name: Sapropterin Dihydrochloride
DrugBank: Sapropterin (DB00360)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sapropterin Dihydrochloride 5 mg/kg twice a day administered as whole tablets orally within 1 hour after morning and evening meals for 13 days and the last dose within 1 hour after a morning meal on Day 14 and Day 28.
Trial: NCT00532844
Drug: Sapropterin Dihydrochloride and Vitamin C
RxNorm normalized name: Sapropterin Dihydrochloride
DrugBank: Sapropterin (DB00360)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sapropterin Dihydrochloride 5 mg/kg and 500 mg Vitamin C twice a day administered as whole tablets orally within 1 hour after morning and evening meals for 13 days and the last dose within 1 hour after a morning meal on Day 14 and Day 28.
Trial: NCT01382771
Drug: Intra-articular corticosteroid injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular injection of 0.5 cc triamcinolone acetonide (40 mg/cc) within each joint
Trial: NCT01382771
Drug: Intra-articular saline injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular injection of 0.5 cc normal saline in each joint
Trial: NCT00335166
Drug: Placebo Comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00997789
Drug: Rebamide
RxNorm normalized name: benzocaine / trimethobenzamide hydrochloride Rectal Suppository [Tebamide]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rebamipide 100 mg Tablet, three times a day
Trial: NCT03278548
Drug: Volulyte 6%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution for infusion
Trial: NCT03278548
Drug: Ionolyte
RxNorm normalized name: Isolyte H
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution for infusion
Trial: NCT04419467
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline
Trial: NCT03132558
Drug: Radiopaque Media
RxNorm normalized name: Stellaria media extract
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01366573
Drug: GSK1521498
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK1521498 20 mg administered with alcohol to determine PK/PD interactions
Trial: NCT01602341
Drug: AN2728 Topical Ointment, 0.5% BID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AN2728 Topical Ointment, 0.5% BID
Trial: NCT00295646
Drug: zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 4 mg q6m
Trial: NCT03175731
Drug: Proton Pump Inhibitors
RxNorm normalized name: Proton pump inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pantoprazole 40mg per day intravenously or orally for 2 weeks after endoscopic treatment.
Trial: NCT03175731
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 40mg per day intravenously or orally for 2 weeks after endoscopic treatment.
Trial: NCT02138812
Drug: BAY1161909
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given orally, with a starting dose of 0.75 mg twice daily from C1D1 onwards in a 2 days on/5 days off dosing schedule as single agent treatment in Cycle 1 (14 days), and from C2D8 onwards in a 2 days on/5 days off dosing schedule in 28-day cycles. For single-dose PK cohort: a single oral dose on C1D1
Trial: NCT00720577
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 40 Mg. tablet, 1 tablet daily
Trial: NCT02377557
Drug: Topical Steroids
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02099825
Drug: d-cycloserine and mifepristone
RxNorm normalized name: D-(+)-cycloserine
DrugBank: Cycloserine (DB00260)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All participants will receive a one-time only dose of both, d-cycloserine and mifepristone at Session 2
Trial: NCT04078204
Drug: placebo Soft Capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo group will receive the Placebo Soft Capsules during the 24-month intervention period. After the 24-month intervention,The placebo group will receive Butylphthalide Soft Capsules for the 6-month open treatment period.
Trial: NCT04067531
Drug: treatment of BV with first Deqularum and then direkt after with vaginal clindamycin
RxNorm normalized name: vaginal ring with progestogen and estrogen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients will get the same treatment
Trial: NCT02855658
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo is composed of corn starch, pigment and minimal dose of 1% SS-1. Patients take 6 gram of experiment medicine three times per day.
Trial: NCT00447967
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fluorouracil 400 mg/m2 infused over 10 min IV and Fluorouracil600 mg/m2 infused over 22 hours IV, Day 1 and 2 (De Grammont regimen)every 2 weeks for 12 cycles
Trial: NCT00447967
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Leucovorin 200 mg/m2 infused over 1 hour IV on day 1 and day 2 (De Grammont regimen) every 2 weeks for 12 cycles
Trial: NCT01822665
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Liquid gelation capsules or tablets of 400 mg strength
Trial: NCT01828840
Drug: epidural fentanyl via PCEA
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03924804
Drug: Ringer's solution acetate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of 2 ml/kg Ringer's solution acetate within 1 hour after induction.
Trial: NCT03924804
Drug: Ringer's solution acetate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of 8ml/kg Ringer's solution acetate within 1 hour after induction.
Trial: NCT03924804
Drug: Ringer's solution acetate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of 16ml/kg Ringer's solution acetate within 1 hour after induction.
Trial: NCT04672135
Drug: REM0046127
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral solution: 100 mg/mL REM0046127
Trial: NCT04672135
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral solution with 0 mg/mL REM0046127
Trial: NCT01991483
Drug: LY2928057
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered intravenously
Trial: NCT01991483
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered intravenously
Trial: NCT04314817
Drug: Any drug used to treat Covid-19
RxNorm normalized name: covid-19, protein subunit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lopinavir/ritonavir, remdesivir, interferon beta-1a, chloroquine and/or azithromycin. This list may be amended at a further date.
Trial: NCT00551889
Drug: celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00551889
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01070979
Drug: Estradiol acetate
RxNorm normalized name: Estradiol Acetate
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablet containing 0.9 mg E3A, daily oral administration.
Trial: NCT01070979
Drug: Estradiol
RxNorm normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablet containing 1 mg estradiol, daily oral administration.
Trial: NCT01474304
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg dose intravenous acetaminophen before craniotomy incision and a second 1000 mg dose intravenous acetaminophen 6 hours after surgery
Trial: NCT00137059
Drug: acetaminophen sustained-release
RxNorm normalized name: acetaminophen Delayed Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00876252
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NaCl
Trial: NCT01605357
Drug: Induced, sustained hypernatremia using hypertonic saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in the experimental arm will receive hypertonic saline to target a serum sodium goal of 150 - 160 mmol/L. All hypertonic saline will be administered intravenously.~Loading phase: Upon enrollment 23.4 % hypertonic saline (volume 20 cc) will be administered via a central venous catheter. A continuous infusion of 3% hypertonic saline will be administered at a rate of 30 cc per hour and titrated every six hours to target a serum sodium goal of 150-160 mmol/L.~Maintenance phase: Titrate serum sodium to 150-160 mmol/L using continuous 3% hypertonic saline infusion.~Discontinuation phase: After 5 days of completed therapy, begin to wean 3% hypertonic saline rate by 10cc every 6 hours. Discontinue hypertonic saline infusion after infusing at a rate of 20cc an hour for 6 hours.~Bolus dosing of hypertonic saline and mannitol are to be administered at the discretion of the provider to treat elevated intracranial pressure based on practice guidelines
Trial: NCT01605357
Drug: Standard of care (hypertonic saline and mannitol; serum sodium)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus dosing of hypertonic saline and mannitol are to be administered at the discretion of the provider to treat elevated intracranial pressure based on practice guidelines. Hyponatremia ( serum sodium \< 135 mmol/L) is to be corrected at the discretion of the provider.
Trial: NCT03554018
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen 500-1000mg every 6 hours
Trial: NCT03554018
Drug: Ibuprofen 600 mg
RxNorm normalized name: ibuprofen 600 MG
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen 600mg every 6 hours
Trial: NCT03554018
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: To match acetaminophen, patients will take one or two capsules every 6 hours
Trial: NCT01154452
Drug: Gamma-Secretase Inhibitor RO4929097
RxNorm normalized name: .GAMMA.-OCTALACTONE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT00587483
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline
Trial: NCT02908581
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally once daily
Trial: NCT02908581
Drug: Iron 150 mg and Folic acid 0.5 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron will be administered with folic acid orally
Trial: NCT01027429
Drug: procaine penicillin and gentamicin
RxNorm normalized name: Penicillin G Procaine
DrugBank: Procaine benzylpenicillin (DB09320)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: procaine penicillin 50,000 units/kg by intramuscular injection once daily for 7 days; gentamicin, 5 mg/kg once daily by intramuscular injection for 7 days
Trial: NCT01027429
Drug: amoxicillin and gentamicin
RxNorm normalized name: vonoprazan and amoxicillin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral amoxicillin 80-90 mg/kg divided in two doses for 7 days intramuscular gentamicin, 5 mg/kg once daily for 7 days
Trial: NCT01027429
Drug: procaine penicillin, gentamicin, amoxicillin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: procaine penicillin, 50,000 IU/kg once daily intramuscular injection plus gentamicin 5 mg/kg once daily intramuscular injection for 2 days, followed by 5 days of oral amoxicillin, 80-90 mg/kg divided in two doses.
Trial: NCT01471821
Drug: antiretroviral treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: antiretroviral treatment
Trial: NCT00971282
Drug: adapalen 0.1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-individual (split-face) comparison: Differin® 0.1% (whole face) will be applied once daily for 4 weeks.~Visits will be conducted weekly for a maximum of 5 visits.
Trial: NCT00670930
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00200967
Drug: beclomethasone HFA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 240 mcg beclomethasone HFA (QVAR, Teva Pharmaceutical Industries)
Trial: NCT01790607
Drug: ONO-2745 /CNS 7056
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01444430
Drug: Symbicort pMDI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients were randomized to Symbicort and assigned to one of the following treatments (based upon ACQ at baseline and prior asthma therapy): Symbicort pMDI 80/4.5 μg x 2 actuations bid (morning and evening) or Symbicort pMDI 160/4.5 μg x 2 actuations bid (morning and evening), for oral inhalation.
Trial: NCT02453555
Drug: Empa + lina highdose placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03468322
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle-only control study medication is the same formulation as investigational product without active ingredient
Trial: NCT00205816
Drug: Tigecycline
RxNorm normalized name: Tigecycline
DrugBank: Tigecycline (DB00560)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00331032
Drug: 3% w/w SPL7013 Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice-daily vaginal application of 3.5 g of VivaGel™ (Carbopol®-based gel with 3% w/w SPL7013) in single use pre-filled applicators.
Trial: NCT00331032
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo gel (Carbopol®-based formulation alone) in single use pre-filled applicators.
Trial: NCT03794557
Drug: PUL-042 Inhalation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PUL-042 Inhalation Solution
Trial: NCT02250976
Drug: Livasupril Cap.160/2mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenofibrate pellet( as micronized fenofibrate 160mg) and Pitavastatin Ca 2mg
Trial: NCT02250976
Drug: Lipilfen cap. 160mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micronized fenofibrate 160mg
Trial: NCT02250976
Drug: Livaro tab. 2mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pitavastatin Ca 2mg
Trial: NCT00376636
Drug: SPP635 (drug)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01146613
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: identical matched placebo x 2, 2xday, 13 weeks
Trial: NCT02217618
Drug: LY2409021
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00538057
Drug: GW685698X & GW642444M
FDA approved: no
EMA approved: no
PMDA approved: no
Description: study drug
Trial: NCT00441766
Drug: AGN 203818
RxNorm normalized name: VITEX AGNUS-CASTUS WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part A: 3 mg AGN203818 capsule every 12 hours for 4 weeks
Trial: NCT00441766
Drug: AGN 203818
RxNorm normalized name: VITEX AGNUS-CASTUS WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part A: 20 mg AGN203818 capsule every 12 hours for 4 weeks
Trial: NCT00441766
Drug: AGN 203818
RxNorm normalized name: VITEX AGNUS-CASTUS WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part A: 60 mg AGN203818 capsule every 12 hours for 4 weeks
Trial: NCT00441766
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part A: placebo capsule every 12 hours for 4 weeks
Trial: NCT04460183
Drug: RESP301, a Nitric Oxide generating solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Product application requires inhalation using a standard handheld nebulizer.
Trial: NCT00225914
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects enter into a six-week, double blind phase, randomized in a 1:1 ratio to paroxetine CR 12.5 mg/day or matching placebo pill; dosing may be adjusted up to 25 mg/day after two weeks, based on treatment response and tolerability.
Trial: NCT04593121
Drug: BIIB107
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as specified in the treatment arm.
Trial: NCT04593121
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as specified in the treatment arm.
Trial: NCT03985280
Drug: Intraaticular steroids and local anesthetic injections
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraaticular steroids and local anesthetic injections